Abstract
Objectives: Circulating interleukin (IL-) 6 increases with the severity of heart failure and it can be also regarded as a prognostic factor. In contrast, recent studies show that temporary elevation of this marker is associated with beneficial effects through survivor activating factor enhancement (SAFE) pathway induction. We hypothesized that this mechanism might also account for the observed experimental and clinical benefits including the pronounced reduction of myocardial infarct size mediated by pressure-controlled coronary sinus occlusion (PICSO).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
